מהמעבדה אל העולם

A novel electrochemical method to degrade fluorinated organic compounds (FOCs), which are recognized globally as major water contaminants. These persistent pollutants contain fluorine-carbon (C-F) bonds and are, therefore, highly stable. The method is simple and cost-effective and can be used in batch and flow systems. The technology was chosen as one of four winners in a challenge organized by Mekorot's innovation unit, WaTech, to receive further funding and mentorship for prototype development. The technology is IP-protected.

A new automated system for the analysis of non-verbal signals in speech. The system detects several emotions and attitudes, as well as spoken emphasis, prosodic unit boundaries and three prosodic prototypes. Potential applications include speech-to-text, machine translation, behavioral analysis, and more. The technology has been transferred to Yeda and is now under commercialization.

A screening platform to identify small molecules that inhibit the fusion of the SARS-CoV-2 virus membrane with host cells. New molecules were identified and successfully tested in a cell-based assay.

A new imaging approach that uses deep learning algorithms integrated in standard imaging methods. This approach increases the efficiency of tissue pathology, enabling the analysis of up to 22 proteins simultaneously while using only five channels. The technology is IP-protected and transferred to Yeda for commercialization.

A new device that is inserted into the ureteroscope working channel intended to remove stone fragments following laser fragmentation (lithotripsy) of kidney or ureteral stones. The new device was designed together with Dr. Yaniv Shilo, an endourologist (Kaplan Medical Center), and industrial designers from Bezalel Academy of Art and it is IP-protected. The project was transferred to Yeda and is under commercialization.

Environmentally friendly, robust supramolecular plastic materials composed of organic nanocrystals. The novel plastics are IP-protected and can be incorporated into biodegradable polymers as an alternative to polluting petroleum-based plastics.

A multidisciplinary collaboration between Prof. Lior Heller, a plastic surgeon, and Prof. Brian Berkowitz, an hydrologist, to develop a device intended for the active drainage of liquids for lymphedema patients. An in-vivo safety experiment was conducted successfully. The new device is IP-protected. The project was transferred to Yeda and is under commercialization

This project develops a small-molecule that induces precise translational errors in cancer cells, generating novel immunogenic peptides that broaden the tumor neoantigen landscape. By enhancing antigen presentation, the approach aims to boost responsiveness to immunotherapies, especially in low-mutational-burden cancers typically non responsive to checkpoint blockade. Supported by mechanistic studies, AI-driven target discovery, and early in vivo evidence, the team is advancing optimized inhibitors toward a new class of broadly applicable cancer-immunotherapy enhancers.

More than 6% of the adult population requires voice therapy, yet access to care is limited by long wait times, workforce shortages, high costs, and the lack of tools for continuous, objective monitoring.
This project aims to develop a digital platform for remote voice therapy that integrates quantitative voice assessment, guided exercises, and longitudinal monitoring. The system will support both patients and speech therapists by enabling real-time feedback, remote supervision, and data-driven adjustments to therapy.
Developed in collaboration with Wolfson Medical Center, the project combines multidisciplinary research expertise with clinical leadership to establish a scalable model of voice therapy that improves outcomes, expands care capacity, and reduces the burden on patients and healthcare systems.
 

This project develops a novel small-molecule strategy to selectively block a key ubiquitination-dependent signaling switch, which modifies microglial activation state to attenuate neuroinflammation.  By damping inflammation this approach offers a novel path to reduce neuroinflammation, a common drive of neurodegeneration progression. Building on PTM-profiling discoveries and encouraging results in cultured microglia and mouse models, the team aims to advance next-generation inhibitors toward a new therapeutic pathway to resolve neuroinflammation across multiple neurodegenerative diseases